Restatement Radar
Numbers that companies quietly changed after they first reported them — each one diffed across two SEC filings, both linked.
32,909 revisions on filemost recent 2026-08-28
CSBRCHAMPIONS ONCOLOGY, INC.
Health Care
Net Income (Loss) Attributable to Parent·FY 2026
Major restatement-$1.2K▲ 99.9%was-$1.2M
Revised up.
No amendment filedESTCElastic N.V.
Information Technology
Net Income (Loss) Attributable to Parent·FY 2022
Major restatement-$236.2K▲ 99.9%was-$203.8M
Revised up.
No amendment filedCSBRCHAMPIONS ONCOLOGY, INC.
3rd largest revision in CSBR's history
Net Income (Loss) Attributable to Parent·FY 2024
Major restatement-$7.3K▲ 99.9%was-$7.3M
Revised up.
No amendment filedFEIMFREQUENCY ELECTRONICS INC
2nd largest revision in FEIM's history
Net Income (Loss) Attributable to Parent·FY 2024
Major restatement$5.6K▼ 99.9%was$5.6M
Revised down.
No amendment filedCSBRCHAMPIONS ONCOLOGY, INC.
2nd largest revision in CSBR's history
Net Income (Loss) Attributable to Parent·FY 2025
Major restatement$4.7K▼ 99.9%was$4.7M
Revised down.
No amendment filedESTCElastic N.V.
2nd largest revision in ESTC's history
Net Income (Loss) Attributable to Parent·FY 2021
Major restatement-$203.8K▲ 99.8%was-$129.4M
Revised up.
No amendment filedFEIMFREQUENCY ELECTRONICS INC
Health Care
Net Income (Loss) Attributable to Parent·FY 2026
Major restatement-$903▲ 99.9%was-$903K
Revised up.
No amendment filedALCYFAlchemy Investments Acquisition Corp 1
Financials
Net Cash Provided by (Used in) Operating Activities·Q2 2025
Major restatement-$470K▲ 24.2%was-$620K
Revised up in a 10-Q.
No amendment filedCRWDCrowdStrike Holdings, Inc.
8th largest revision in CRWD's history
Operating Income (Loss)·Q2 2025
Notable restatement-$105.5M▲ 6.7%was-$113M
Revised up in a 10-Q.
No amendment filedCRWDCrowdStrike Holdings, Inc.
6th largest revision in CRWD's history
Net Income (Loss) Attributable to Parent·Q2 2025
Notable restatement-$70.2M▲ 9.7%was-$77.7M
Revised up in a 10-Q.
No amendment filedCRWDCrowdStrike Holdings, Inc.
5th largest revision in CRWD's history
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q2 2025
Major restatement-$64.2M▲ 10.5%was-$71.7M
Revised up in a 10-Q.
No amendment filedCNFNCFN Enterprises Inc.
Industrials
Revenues·Q2 2025
Major restatement$6.3K▼ 100.0%was$18.7M
Revised down in a 10-Q.
No amendment filedCNFNCFN Enterprises Inc.
3rd largest revision in CNFN's history
Gross Profit·Q2 2025
Major restatement$6.2K▼ 99.2%was$774.4K
Revised down in a 10-Q.
No amendment filedCNFNCFN Enterprises Inc.
7th largest revision in CNFN's history
Operating Income (Loss)·Q2 2025
Major restatement-$331.8K▲ 84.8%was-$2.2M
Revised up in a 10-Q.
No amendment filedRLYBRallybio Corp
Health Care
Revenues·FY 2024
Notable restatement$636K▲ 6.0%was$600K
Revised up. Any P/S built on the original was 5.7% too high.
No amendment filedQDMIQDM International Inc.
Financials
Operating Income (Loss)·Q1 2025
Major restatement$2.2M▼ 15.9%was$2.6M
Revised down.
No amendment filedQDMIQDM International Inc.
2nd largest revision in QDMI's history
Net Income (Loss) Attributable to Parent·Q1 2025
Major restatement$1.9M▼ 15.7%was$2.2M
Revised down. Any P/E built on the original was 18.6% too low.
No amendment filedAGMHAGM GROUP HOLDINGS, INC.
4th largest revision in AGMH's history
Gross Profit·FY 2023
Major restatement$3.2M▼ 31.9%was$4.6M
Revised down.
No amendment filedQDMIQDM International Inc.
4th largest revision in QDMI's history
Gross Profit·Q1 2025
Major restatement$2.5M▼ 14.0%was$3M
Revised down.
No amendment filedQDMIQDM International Inc.
3rd largest revision in QDMI's history
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q1 2025
Major restatement$2.2M▼ 15.6%was$2.6M
Revised down.
No amendment filedAGMHAGM GROUP HOLDINGS, INC.
5th largest revision in AGMH's history
Revenues·FY 2023
Major restatement$68.8M▼ 26.0%was$92.9M
Revised down. Any P/S built on the original was 35.1% too low.
No amendment filedCHGAChange Agents Corporation.
3rd largest revision in CHGA's history
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·FY 2024
Major restatement-$7M▲ 10.9%was-$7.9M
Revised up.
No amendment filedNTCSNatics Corp.
2nd largest revision in NTCS's history
Stockholders' Equity Attributable to Parent·As of Apr 30, 2024
Major restatement-$16.4K▼ 84.5%was-$8.9K
Revised down in a 10-Q.
No amendment filedNTCSNatics Corp.
Information Technology
Stockholders' Equity Attributable to Parent·As of Apr 30, 2023
Major restatement-$6.4K▼ 100.8%was-$3.2K
Revised down in a 10-Q.
No amendment filedCNTMConnectM Technology Solutions, Inc.
3rd largest revision in CNTM's history
Assets·As of Jun 30, 2025
Major restatement$15.5M▼ 29.0%was$21.8M
Revised down in a 10-Q.
No amendment filedCNTMConnectM Technology Solutions, Inc.
10th largest revision in CNTM's history
Operating Income (Loss)·Q2 2025
Notable restatement-$3.5M▼ 6.7%was-$3.3M
Revised down in a 10-Q.
No amendment filedCNTMConnectM Technology Solutions, Inc.
9th largest revision in CNTM's history
Revenue from Contract with Customer, Excluding Assessed Tax·Q2 2025
Notable restatement$7.9M▼ 7.4%was$8.5M
Revised down in a 10-Q. Any P/S built on the original was 7.9% too low.
No amendment filedCNTMConnectM Technology Solutions, Inc.
Industrials
Net Income (Loss) Attributable to Parent·Q2 2025
Major restatement-$4.8M▼ 35.3%was-$3.5M
Revised down in a 10-Q.
No amendment filedBGMSBio Green Med Solution, Inc.
8th largest revision in BGMS's history
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q2 2025
Notable restatement-$1.2M▲ 5.2%was-$1.3M
Revised up.
No amendment filedBGMSBio Green Med Solution, Inc.
9th largest revision in BGMS's history
Operating Income (Loss)·Q2 2025
Notable restatement-$1.2M▲ 5.2%was-$1.3M
Revised up.
No amendment filedCNSPCNS Pharmaceuticals, Inc.
2nd largest revision in CNSP's history
Net Income (Loss) Attributable to Parent·FY 2024
Major restatement-$14.9K▲ 99.9%was-$14.9M
Revised up.
No amendment filedCNSPCNS Pharmaceuticals, Inc.
Health Care
Net Income (Loss) Attributable to Parent·FY 2023
Major restatement-$18.9K▲ 99.9%was-$18.9M
Revised up.
No amendment filedCNSPCNS Pharmaceuticals, Inc.
3rd largest revision in CNSP's history
Net Income (Loss) Attributable to Parent·FY 2025
Major restatement-$16K▲ 99.9%was-$15.9M
Revised up.
No amendment filedNIVFNewGenIvf Group Ltd
5th largest revision in NIVF's history
Comprehensive Income (Loss), Net of Tax, Attributable to Parent·FY 2023
Major restatement$85.7K▼ 24.4%was$113.3K
Revised down.
No amendment filedRMTGRegenerative Medical Technology Group Inc.
Consumer Staples
Net Income (Loss) Attributable to Parent·Q2 2025
Major restatement-$1.4M▼ 10.6%was-$1.3M
Revised down in a 10-Q.
No amendment filedRMTGRegenerative Medical Technology Group Inc.
3rd largest revision in RMTG's history
Stockholders' Equity Attributable to Parent·As of Dec 31, 2025
Notable restatement-$36M▼ 3.8%was-$34.7M
Revised down in a 10-Q.
No amendment filedRMTGRegenerative Medical Technology Group Inc.
8th largest revision in RMTG's history
Stockholders' Equity Attributable to Parent·As of Mar 31, 2026
Notable restatement-$36.4M▼ 2.1%was-$35.6M
Revised down in a 10-Q.
No amendment filedRMTGRegenerative Medical Technology Group Inc.
6th largest revision in RMTG's history
Liabilities·As of Dec 31, 2025
Notable restatement$40.5M▲ 3.3%was$39.2M
Revised up in a 10-Q.
No amendment filedOPTTOcean Power Technologies, Inc.
Utilities
Net Income (Loss) Attributable to Parent·FY 2025
Major restatement-$24.5M▼ 13.7%was-$21.5M
Revised down in a 10-K.
No amendment filedOPTTOcean Power Technologies, Inc.
2nd largest revision in OPTT's history
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·FY 2025
Major restatement-$25.5M▼ 13.1%was-$22.5M
Revised down in a 10-K.
No amendment filed